1-氨基苯并三唑作用機制 - Medchemexpress - MCE中國

1、Product Data Sheet1-AminobenzotriazoleCat. No.: HY-103389CAS No.: 1614-12-6分式: CHN分量: 134.14作靶點: Cytochrome P450作通路: Metabolic Enzyme/Protease儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 125 mg/mL (931.86 mM; Need ultrasonic)H2O : 50 mg/mL (372.74 mM; Need u

2、ltrasonic)SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 7.4549 mL 37.2745 mL 74.5490 mL5 mM 1.4910 mL 7.4549 mL 14.9098 mL10 mM 0.7455 mL 3.7274 mL 7.4549 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲存時，請在 6 個內(nèi)使，-20C 儲存時，請在 1 個內(nèi)使。體內(nèi)實驗請根據(jù)您的

3、實驗動物和給藥式選擇適當(dāng)?shù)娜芙獍?。以下溶解案都請先按?In Vitro 式配制澄清的儲備液，再依次添加助溶劑：為保證實驗結(jié)果的可靠性，澄 的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (15.51 mM); Clear solution此案可獲得 2.08 mg/mL (15.51 mM，飽

4、和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 20.8 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (15.51 mM); Clear solutionPage 1 of 2 www.MedChemE此案可獲得 2.08 mg/mL (15.51 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取

5、 100 L 20.8 mg/mL 的澄 DMSO 儲備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合均勻。3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.08 mg/mL (15.51 mM); Clear solution此案可獲得 2.08 mg/mL (15.51 mM，飽和度未知) 的澄 溶液，此案不適于實驗周 期在半個以上的實驗。以 1 mL 作液為例，取 100 L 20.8 mg/mL 的澄 DMSO 儲備液加到 900 L 油中，混合均勻。BIOLOGICAL ACTIVITY物活性 1-Aminobenzot

6、riazole細(xì)胞素 P450 (P450) 的特異且不可逆抑制劑。IC & Target P4501體外研究 1-Aminobenzotriazole (ABT) alone significantly increases the expression levels of CYP2B6 in two different hepatocytes(7.3- and 10.8-fold, respectively). Upon co-treatment with 1-Aminobenzotriazole, the induction of CYP2B6 expressionby CITCO or

7、rifampin is potentiated: 12.6- and 4.0-fold for CITCO as well as 3.9- and 2.5-fold for rifampin. 1-Aminobenzotriazole has a greater potentiation effect on CITCO than on rifampin. 1-Aminobenzotriazole aloneincreases the expression levels of CYP3A4 in tow different hepatocytes (by 2.0- and 3.8-fold).

8、Upon co-treatment with1-Aminobenzotriazole, the effects of CITCO on CYP3A4 expression levels are potentiated by 3.8- and 6.0- fold ascompare to cells treated with CITCO alone1. 1-Aminobenzotriazole (ABT) (1 mM) shows pronounced (95%)inhibition of the formation of N-acetylprocainamide compare with th

9、e control without 1-Aminobenzotriazole2.體內(nèi)研究 Oral 1-Aminobenzotriazole (ABT) (100 mg/kg, 2 h predose) decreases the clearance of intravenous procainamide(45%) in rats, accompanied by a decreased N-acetylprocainamide-to-procainamide ratio in urine (0.74 versus 0.21)and plasma (area under the curve ra

10、tio 0.59 versus 0.11). The urinary recovery of procainamide increases from 18 to30%, whereas the recovery of N-acetylprocainamide in urine decreases from 13.3 to 6.5% with 1-Aminobenzotriazole2. Pretreatment of rats with 100 mg/kg oral 1-Aminobenzotriazole (ABT) administered 2 hours before a semisol

11、idcaloric test meal markedly delays gastric emptying. 1-Aminobenzotriazole also increases stomach weights by 2-fold3.PROTOCOLCell Assay 1 Freshly isolated human hepatocytes are used in this study. Briefly, hepatocytes are placed in serum-free Williams Emedia containing 0.1 M dexamethasone, 10 g/mL g

12、entamicin, 15 mM HEPES, 2 mM L-glutamine, and 1% ITS. Cellsare incubated for 10 hr at 37C in an atmosphere containing 5% CO2. After recovery, the hepatocytes are treated withmedia containing CITCO (100 nM), rifampin (10 M) or vehicle (ethanol), with or without 1-Aminobenzotriazole(ABT) (1 mM) for 72

13、 hr1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Male Sprague-Dawley rats (0.26 to 0.30 kg, n=3 per treatment) receive an oral dose of 1-Aminobenzotriazole (ABT)Administration 2 (100 mg/kg, 2 mL/kg) 2 h before a single intravenous bolus of pr

14、ocainamide (10 mg/kg, 2 mL/kg). The control groupreceives only the intravenous bolus of procainamide without 1-Aminobenzotriazole pretreatment. The vehicle forboth 1-Aminobenzotriazole and procainamide is 10% dimethylacetamide/90% water (v/v). Rats are fed 4 h afterdosing, and serial blood samples a

15、re collected at 0.03, 0.17, 0.25, 0.5, 1, 2, 4, and 6 h postdose. Blood samples arecentrifuged using tubes containing K3-EDTA as the anticoagulant to obtain plasma. Urine samples are also collectedover 24 h postdose. Plasma and urine samples are frozen at -20C until analysis2.Page 2 of 3 www.MedChem

16、EMCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Yang K, et al. Induction of CYP2B6 and CYP3A4 expression by 1-aminobenzotriazole (ABT) in human hepatocytes. Drug Metab Lett. 2010 Aug;4(3):129-33.2. Sun Q, et al. 1-Aminobenzotriazole, a known cytochrome P450 inhibitor, is a substrate and inhibitor of N-acetyltransferase. Drug Metab Dispos. 2011Sep;39(9):1674-9.3. Stringer RA, et al. 1-Aminobenzotriazole modulates oral drug pharmacokinetics through cytochrome P450 inhibition and delay of gastric emptying inrats. Drug Met